Ammu Kutty Radhakrishnan | Cancer Immunology | Best Researcher Award

Posted on by ScienceFather

Prof. Ammu Kutty Radhakrishnan | Cancer Immunology | Best Researcher Award

Prof. Ammu Kutty Radhakrishnan, Monash University Malaysia, Malaysia

 

Prof. Ammu Kutty Radhakrishnan is a distinguished immunologist with a PhD from the University of Cambridge (1994), an MSc in Biochemistry (1990), and a BSc (First Class Honours) from the University of Malaya (1987). Currently, a Professor of Immunology at Monash University Malaysia, she has over 25 years of academic leadership and research experience. Prof. Ammu specializes in immunotherapy and food as medicine research, serving as Head of this research strength. Her career spans significant roles at International Medical University and Oxford. She is a research consultant, active in COVID-19 vaccine efforts, and supervises PhD and MSc students. 🌿🧬📚

 

Publication Profile

Google Scholar

Academic Excellence

Prof. Ammu Kutty Radhakrishnan has an exceptional academic background, with a PhD in Immunology from the University of Cambridge (1994) and degrees in Biochemistry from the University of Malaya. Her education forms a solid foundation for her expertise in immunology and biomedical sciences, contributing to her distinguished career.

Professional Experience

Prof. Radhakrishnan has held key roles, such as Professor at Monash University Malaysia and the International Medical University (IMU). Her leadership in academic programs, such as head of the Food as Medicine Research Strength and chief examiner roles, showcases her commitment to advancing education and research.

Research Contributions

Prof. Radhakrishnan has supervised numerous PhD and Master’s students, guiding 39 doctoral and 20 master’s research projects to completion. Her extensive research supervision experience highlights her dedication to fostering scientific inquiry and innovation. Additionally, her collaborative efforts with industry partners demonstrate her ability to apply research to real-world problems.

Conclusion

Prof. Ammu Kutty Radhakrishnan’s outstanding academic credentials, extensive research supervision, leadership roles, and global health contributions, she is an ideal candidate for the Best Researcher Award. Her work in immunology, biomedicine, and collaboration with industry partners demonstrates her excellence in both academic and applied research, making her a worthy contender for this prestigious recognition.

 

Publication Top Notes  

  • Protective effect of aqueous extract from Spirulina platensis against cell death induced by free radicals (2010) – 292 citations 🧪
  • Human cell-adhesion molecule CD2 binds CD58 (LFA-3) with very low affinity and an extremely fast dissociation rate but does not bind CD48 or CD59 (1994) – 259 citations 🧬
  • Rind of the rambutan, Nephelium lappaceum, a potential source of natural antioxidants (2008) – 193 citations 🍇
  • Current concepts of neurodegenerative mechanisms in Alzheimer’s disease (2018) – 176 citations 🧠
  • Bioactive Compounds: Natural Defense Against Cancer? (2019) – 169 citations 🌿
  • Protective mechanisms of flavonoids in Parkinson’s disease (2015) – 162 citations 🧑‍⚕️
  • Tocotrienol research: past into present (2012) – 157 citations 🌰
  • Standardised Mangifera indica extract is an ideal antioxidant (2009) – 149 citations 🥭
  • Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson’s disease (2020) – 128 citations 🚀
  • Tocotrienol-rich fraction from palm oil affects gene expression in tumors resulting from MCF-7 cell inoculation in athymic mice (2004) – 126 citations 🧫
  • Rutin, a bioflavonoid antioxidant protects rat pheochromocytoma (PC-12) cells against 6-hydroxydopamine (6-OHDA)-induced neurotoxicity (2013) – 124 citations 🧪

 

Dr Gabriel Espinosa Carrasco | Immunotherapy | Best Researcher Award

Posted on by ScienceFather

 Gabriel Espinosa Carrasco | Immunotherapy | Best Researcher Award

Dr at Memorial Sloan Kettering Cancer Center,Spain.

Dr. Gabriel Espinosa Carrasco is a distinguished immunologist affiliated with Memorial Sloan Kettering Cancer Center. His research primarily focuses on T cell activation and the mechanisms of self-antigen recognition in immunology. Dr. Espinosa Carrasco’s work advances our understanding of immune responses in various contexts, bridging the gap between basic science and clinical applications.

Profile:

orcid

Education:

  1. Ph.D. in Biological Sciences and Immunology (2011-2016)
    University of Montpellier, INSERM Unit 1183 (France)
    Title: CD8+ and CD4+ T cell activation in response to self-antigens: from the lymphoid tissue to the target organ.
  2. Master in Advanced Immunology (2010-2011)
    University of Barcelona (UB), Barcelona (Spain)
  3. Bachelor’s Degree in Biology (2004-2010)
    Autonomous University of Barcelona (UAB), Barcelona (Spain)

Research Experience:

  1. Post-doctoral Scholar (2022-now)
    Cancer Virotherapy and Immunotherapy Group, Bellvitge Institute for Biomedical Research (IDIBELL)
    Department: Molecular Mechanisms and Experimental Therapy in Oncology
    Supervisor: Dr. Ramon Alemany
    🌟 Focus: Investigating novel virotherapy and immunotherapy approaches for cancer treatment.
  2. Post-doctoral Research Scholar (2017-2022)
    Memorial Sloan-Kettering Cancer Center, Immunology Program, New York
    Project: Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors.
    Supervisor: Dr. Andrea Schietinger
    🔬 Focus: Enhancing the effectiveness of immunotherapies in solid tumors.
  3. Ph.D. Student (2011-2016)
    INSERM Unit 1183, Montpellier
    Projects:
    a) Study the cooperation of effector CD8+ and CD4+ T cells in pancreas infiltration and beta cell destruction in real-time.
    b) Role of bacterial product translocation in the breakdown of CD8+ T cell peripheral tolerance under lymphopenic conditions.
    Supervisor: Dr. Javier Hernández
    📚 Focus: Understanding T cell interactions and their role in autoimmune responses.
  4. Master Internship (2010-2011)
    Institute of Biotechnology and Biomedicine, Barcelona
    Analysis of peptides directory associated with HLA class I molecules from human thymus and spleen.
    Supervisor: Dr. Iñaki Alvarez
    🔬 Focus: Peptide analysis and immune recognition.
  5. Bachelor’s Internship (2008-2009)
    Institute of Biotechnology and Biomedicine, Barcelona
    Composition analysis of the HLA-DR-associated human thymus peptidome.
    Supervisor: Dr. Iñaki Alvarez
    🔬 Focus: Immune system peptide composition.

Research Interests:

Dr. Espinosa Carrasco’s research primarily focuses on T cell activation, self-antigen recognition, and the development of new therapeutic strategies for autoimmune diseases and cancer immunotherapy. His work aims to elucidate the complex interactions within the immune system to enhance treatment efficacy

Awards and Honors:

  • 2024: Provisionally selected for the “Best Researcher Award 2024” (ACA awards)
  • 2022: Selected Speaker, Recent insights into Immuno-Oncology, Leuven, Belgium
  • 2021-2022: Grant recipient, Ludwig Center Basic and Translational Immunology Postdoctoral RFA Memorial Sloan Kettering Cancer Center, New York, USA. $100,000/year
  • 2019: Third prize poster presentation award, Tumor Microenvironments: Mechanisms and Therapeutic Implication 6th Annual Symposium, New York, USA
  • 2017: Invited seminar speaker, Georgetown University, Department of Microbiology and Immunology
  • 2016: Excelente Cum Laude Tesis Doctoral, University of Montpellier, Montpellier, France
  • 2015: Best poster presentation award, Institute for Regenerative Medicine and Biotherapy Annual Retreat, Montpellier, France
  • 2014: Travel Grant, European Association for the Study of Diabetes conference
  • 2012-2015: Research grant from the French Ministry of Research (MRT scholarship), €21,000/year
  • 2009-2010: ERASMUS scholarship from the Autonomous University of Barcelona (UAB), University of Nancy

Publications:

  • Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell, 2024. Link.
  • TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. J Exp Med, 2022. Link.
  • Fate bifurcation of beta cell-specific CD8 T cells drives type 1 diabetes. Nature, 2022. Link.
  • Cytotoxic CD8+ T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons. Proc Natl Acad Sci USA, 2019. Link.
  • Integrin beta 1 optimizes diabetogenic T cell migration and function in the pancreas. Frontiers in Immunology, 2018. Link.
  • CD4+ T helper cells play a key role in maintaining diabetogenic CD8+ T cell function in the pancreas. Frontiers in Immunology, 2018. Link.
  • Gilz-Activin A as a Novel Signaling Axis Orchestrating Mesenchymal Stem Cell and Th17 Cell interplay. Theranostics, 2018. Link.
  • PPARβ/δ directs the therapeutic potential of mesenchymal stem cells in arthritis. Annals of the Rheumatic Diseases, 2016. Link.
  • Metabolism Regulates Exposure of Pancreatic Islets to Circulating Molecules In Vivo. Diabetes, 2016. Link.
  • Systemic LPS Translocation Activates Cross-Presenting Dendritic Cells but Is Dispensable for the Breakdown of CD8+ T Cell Peripheral Tolerance in Irradiated Mice. PLoS One, 2015. Link.